So SGY is back to only $2.10 pre split?
survival cap is $250 million with current oil/gas prices.
I'll tell you why I think SGY is a $30 stock.
XCO has a market cap of $340 million with lower production, more debt, less cash, and less revenue.
SGY deserves a comparable valuation. At an $80 million cap a comparable valuation would be over 3x the current share price. Thus $30-40 a share.
Now you can make the case that XCO is overvalued if you prefer to see the short side. Short XCO and long SGY is a safe way to play oil.
Sure (I'm long). BR is a strong possibility if oil is $35ish for an extended period of time. If oil is plus $50 for the next year we will see a market cap of $150 million easy (up 2X).
Tell me where oil is and I will tell you what the share price will be.
Look up the term Occam's Razor.
' Among competing hypotheses, the one with the fewest assumptions should be selected.'
SGY share price bounce is simply following the increase in Oil & Gas prices plus the reduction in expenses. If those prices go to $60 for oil then SGY deserves a modest $100 million market cap. If it falls then nothing.
Why don't you see the obvious?
Somebody got a jump on the Ensco news today. I started to buy more based on the options action.
of that? 341K x 365 = $123 million.
Am I right?
If so, this is HUUUGE as some loudmouth I saw on TV said.
Now it could be nervous shorts buying the calls - or smart money longs.
Won't know for a while
my other O&G (WLL) is getting killed.
The volume is down a little (not counting the Russell rebalance on Friday).
You don't know what dilution is, do you?
No, they don't need to raise more capital - at least for two-three years. So there won't be dilution.
What they need is a product to sell.
as a one time dividend.
But that won't happen.
From their last earnings release:
"At March 31, 2016, ProNAi had $140.9 million in cash and cash equivalents compared to $150.2 million in cash and cash equivalents at December 31, 2015."
they are losing $10 million a quarter.
I just went long by the way.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) continues to plan for FDA approval of oral Relistor, a treatment for opioid-induced constipation, on its July 19, 2016 PDUFA date. If approved, Progenics would be entitled to a $50 million milestone payment and subsequent sales royalties and commercial milestones from its partner Valeant.
According to Brean Capital analyst Jonathan Aschoff, the limited bioavailability of oral Relistor compared to Relistor SQ, which has been on the market for eight years, should get the FDA around any safety concerns as blood levels are vastly lower with the oral. The FDA asked for the pivotal oral Relistor trial to demonstrate that the pill had a higher response rate and greater tolerability than the currently approved injection, and the trial delivered on both.
I bought at $16 early in May so don't accuse me of pumping and dumping.
But some buyer will kick in the HFT buying soon.
That debt was there six months ago when the share price was $60.
What has changed is guidance and management credibility. But does that justify a 75% haircut?
Yeah, I bought the day it got hammered and rode it down to 13ish.
I just hate to sit out rallies. This is a big two day market rally you have to admit. And yes, I wish I had done what you did.